Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes
Open Access
- 14 September 2009
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 32 (12) , 2263-2268
Abstract
OBJECTIVE Patients with type 2 diabetes are known to have an increased risk for fracture compared with non–type 2 diabetic control subjects, despite having higher bone mineral density (BMD). We previously showed that serum pentosidine, one of the advanced glycation end products (AGEs), was associated with prevalent vertebral fractures (VFs) in those with type 2 diabetes. The involvement of the endogenous secretory receptor for AGEs (esRAGE) in VFs in those with type 2 diabetes, however, is still unknown. RESEARCH DESIGN AND METHODS We compared parameters including esRAGE, pentosidine, and BMD in Japanese type 2 diabetic patients (137 men >50 years old and 140 postmenopausal women) with and without VFs. RESULTS The esRAGE-to-pentosidine ratio in type 2 diabetic patients with VFs was significantly lower than in those without VFs (men: 7.1 ± 2.8 vs. 9.4 ± 6.2, P = 0.013, respectively; women: 4.7 ± 2.7 vs. 8.2 ± 5.4, P < 0.001, respectively). Multivariate logistic regression analysis adjusted for age, BMI, A1C, serum creatinine, duration of diabetes, therapeutic agents, diabetes complications, osteoporotic risk factors, and lumbar BMD identified the serum esRAGE level and esRAGE-to-pentosidine ratio as factors associated with the presence of VFs, independent of BMD in men (odds ratio [OR] 0.46 [95% CI 0.25–0.84], P = 0.012; and OR 0.34 [0.15–0.76], P = 0.009, respectively) and in women (OR 0.32 [0.16–0.67], P = 0.002; and OR 0.14 [0.04–0.43], P = 0.001, respectively). CONCLUSIONS These results show that serum esRAGE level and esRAGE-to-pentosidine ratio are more useful than BMD for assessing the risk of VFs in type 2 diabetic patients.Keywords
This publication has 26 references indexed in Scilit:
- Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic ComplicationsJournal of Bone and Mineral Research, 2009
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCanadian Medical Association Journal, 2009
- The Combination of High Glucose and Advanced Glycation End-products (AGEs) Inhibits the Mineralization of Osteoblastic MC3T3-E1 Cells through Glucose-induced Increase in the Receptor for AGEsHormone and Metabolic Research, 2007
- Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone lossBiochemical and Biophysical Research Communications, 2006
- Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injuryBiochemical Journal, 2003
- N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene ExpressionJournal of Biological Chemistry, 1999
- Advanced Glycation Endproducts Stimulate Interleukin-6 Production by Human Bone-Derived CellsJournal of Bone and Mineral Research, 1997
- ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGINGAnnual Review of Medicine, 1995
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993